Global Opioid Use Disorder Market Report and Forecast 2024-2032

Global Opioid Use Disorder Market Report and Forecast 2024-2032

Market Outlook

According to the report the global opioid use disorder market is projected to grow at a CAGR of 10% between 2024 and 2032 to reach a value of about USD 7.8 billion by 2032. Aided by the escalating cases of opioid abuse and the burgeoning need for effective treatments and interventions, the market is expected to grow significantly by 2032.

Opioid use disorder (OUD) represents a chronic neurobiological condition characterised by an individual's repeated use of opioids, whether they be prescription medications or illicit substances like heroin. The consequences range from health-related issues, compromised social engagements, and a pronounced decline in the overall quality of life. The disorder’s manifestations can be multifaceted, inclusive of a strong drug craving, an inability to control or reduce consumption, and the emergence of withdrawal symptoms upon abrupt cessation.

The burgeoning incidence rate of opioid use disorder worldwide is primarily driving the opioid use disorder market growth. A heightened understanding of the debilitating nature of OUD has led to more focused efforts on prevention, early detection, and effective therapeutic interventions. In addition, the increasing prescription rate of opioid analgesics, often coupled with misuse, has ignited the pressing need for optimal treatment strategies.

Pharmaceutical advancements in opioid use disorder treatment have been influencing the global opioid use disorder market outlook. Medications such as buprenorphine, methadone, and naltrexone have gained prominence for their efficacy in not only managing withdrawal symptoms but also in reducing the likelihood of relapse. These drugs, when amalgamated with psychosocial support, have illustrated promising outcomes in the recovery trajectory of OUD patients.

Beyond pharmaceuticals, the increasing advocacy for comprehensive therapeutic approaches is augmenting the OUD market. Cognitive-behavioural therapy, contingency management, and motivational enhancement therapy are all gaining traction. These approaches, which aim at modifying the patient's thinking patterns and behaviours, hold promise in conjunction with medication-assisted treatments.

As per the opioid use disorder market analysis, the health sector's growing inclination towards technology and digital health also promises to reshape the market dynamics. Digital therapeutic solutions, inclusive of mobile apps and online support groups, are emerging as effective tools. They offer patients round-the-clock support, monitor drug usage patterns, and facilitate immediate interventions during craving episodes.

In addition, the increasing governmental and non-governmental interventions, in the form of awareness campaigns, are playing an indispensable role in highlighting the risks associated with opioid misuse and the potential pathways to recovery. These initiatives, backed by policies that stress regular physician training on opioid prescription and monitoring, are creating a robust infrastructure for combatting the OUD epidemic.

Market Segmentation

The market can be divided based on drug and region.

Market Breakup by Drug

• Buprenorphine
• Bunavail
• Sublocade
• Suboxone
• Zubsolv
• Others
• Methadone
• Naltrexone

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global opioid use disorder market. Some of the major players explored in the report are as follows:

• Indivior PLC
• BioDelivery Sciences International, Inc.
• Alkermes plc
• Titan Pharmaceuticals, Inc.
• Camurus AB.
• Others